Karuna Therapeutics, Inc. ((KRTX)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Karuna Therapeutics, Inc. is conducting a Phase 3 global, multicenter, open-label extension study titled A Phase 3 Global, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer’s Disease. The primary objective is to evaluate the long-term safety and tolerability of KarXT in individuals with Alzheimer’s-related psychosis, highlighting its significance in addressing this challenging condition.
The study tests KarXT, a drug combining Xanomeline and Trospium Chloride, aimed at treating psychosis in Alzheimer’s patients. KarXT is administered in capsule form, with varying doses to assess its effectiveness and safety over an extended period.
This interventional study follows a single-group assignment model without masking, focusing on treatment as its primary purpose. Participants from previous related studies are enrolled to continue assessing KarXT’s safety and tolerability.
The study began on July 11, 2023, with primary completion and estimated completion dates set for July 14, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could influence market dynamics.
The update on this study could impact Karuna Therapeutics’ stock performance and investor sentiment, as positive results may enhance the company’s competitive position in the Alzheimer’s treatment market. Investors should watch for developments, as success could shift industry dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.